Research progress of CA125 and BDNF in serum of patients with acute myocardial infarction for predicting acute heart failure.
Clin Hemorheol Microcirc
; 75(1): 99-106, 2020.
Article
em En
| MEDLINE
| ID: mdl-31868662
ABSTRACT
BACKGROUND:
At present, the treatment for acute myocardial infarction has achieved great progress. Reperfusion therapy in the short term can effectively reduce recurrence rates and mortality in patients with acute myocardial infarction. According to a report of a large national registry, the mortality of patients with acute coronary syndrome combined with acute heart failure is 10 times of that of patients without heart failure, and the mortality in nearly 10 years has no significant change. Therefore, people are constantly exploring indicators for acute heart failure prognosis to improve a patient's prognosis. With the constant understanding and exploration of acute myocardial infarction, more and more researches have focused in determining how to predict the occurrence of acute heart failure. The present study focuses on presenting the latest progress of Carbohydrate Antigen-125 (CA125) and Brain Derived Neurotrophic Factor (BDNF) in serum of patients with acute myocardial infarction in predicting acute heart failure.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Antígeno Ca-125
/
Fator Neurotrófico Derivado do Encéfalo
/
Insuficiência Cardíaca
/
Infarto do Miocárdio
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Hemorheol Microcirc
Ano de publicação:
2020
Tipo de documento:
Article